Design and application of CCR8 antagonists.
作者信息
Van Loy Tom, Schols Dominique, De Jonghe Steven
机构信息
KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular, Structural and Translational Virology Research Group, Leuven, Belgium.
出版信息
Future Med Chem. 2025 Apr;17(7):747-749. doi: 10.1080/17568919.2025.2476381. Epub 2025 Mar 10.
Abstract
摘要
相似文献
1
Design and application of CCR8 antagonists.CCR8拮抗剂的设计与应用。
Future Med Chem. 2025 Apr;17(7):747-749. doi: 10.1080/17568919.2025.2476381. Epub 2025 Mar 10.
2
Identification of novel human CC chemokine receptor 8 (CCR8) antagonists via the synthesis of naphthalene amide and sulfonamide isosteres.通过合成萘酰胺和磺酰胺等排体来鉴定新型人 C 型趋化因子受体 8（CCR8）拮抗剂。
Bioorg Chem. 2024 Apr;145:107181. doi: 10.1016/j.bioorg.2024.107181. Epub 2024 Feb 8.
3
Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration.口服生物利用度变构 CCR8 拮抗剂抑制树突状细胞、T 细胞和嗜酸性粒细胞迁移。
Biochem Pharmacol. 2012 Mar 15;83(6):778-87. doi: 10.1016/j.bcp.2011.12.021. Epub 2011 Dec 24.
4
Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.分子抑制趋化因子受体 CCR8 的要求——探针依赖的变构相互作用。
Br J Pharmacol. 2012 Nov;167(6):1206-17. doi: 10.1111/j.1476-5381.2012.02076.x.
5
HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.人疱疹病毒8型编码的病毒巨噬细胞炎症蛋白-I选择性结合趋化因子受体CCR8。病毒趋化因子的激动剂和拮抗剂特性。
J Biol Chem. 1999 Jul 30;274(31):21569-74. doi: 10.1074/jbc.274.31.21569.
6
Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8.人 CC 趋化因子受体 8 的抗体抑制和趋化因子激活的结构基础。
Nat Commun. 2023 Dec 1;14(1):7940. doi: 10.1038/s41467-023-43601-8.
7
Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist.CCR8激动剂和拮抗剂的结构/功能关系。CCL1的氨基末端延伸一个氨基酸会产生一个部分激动剂。
J Biol Chem. 2006 Dec 1;281(48):36652-61. doi: 10.1074/jbc.M605584200. Epub 2006 Oct 5.
8
Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer.发现一种用于治疗癌症的强效且选择性的CCR8小分子拮抗剂IPG7236。
J Med Chem. 2023 Apr 13;66(7):4548-4564. doi: 10.1021/acs.jmedchem.3c00030. Epub 2023 Mar 29.
9
Targeting the glucocorticoid receptor-CCR8 axis mediated bone marrow T cell sequestration enhances infiltration of anti-tumor T cells in intracranial cancers.靶向糖皮质激素受体-CCR8 轴介导的骨髓 T 细胞隔离可增强颅内癌症中抗肿瘤 T 细胞的浸润。
Cell Mol Immunol. 2024 Oct;21(10):1145-1157. doi: 10.1038/s41423-024-01202-5. Epub 2024 Jul 23.
10
Design, molecular characterization and therapeutic investigation of a novel CCR8 peptide antagonist that attenuates acute liver injury by inhibiting infiltration and activation of macrophages.一种新型CCR8肽拮抗剂的设计、分子特征及治疗研究，该拮抗剂通过抑制巨噬细胞浸润和活化减轻急性肝损伤。
Acta Pharm Sin B. 2025 Apr;15(4):2114-2133. doi: 10.1016/j.apsb.2025.02.018. Epub 2025 Feb 21.
本文引用的文献
1
The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18.趋化因子受体 CCR8 不是人源趋化因子 CCL18 的高亲和力受体。
PLoS One. 2024 Sep 11;19(9):e0305312. doi: 10.1371/journal.pone.0305312. eCollection 2024.
2
G Protein-Coupled Receptors: A Century of Research and Discovery.G 蛋白偶联受体：一个世纪的研究与发现。
Circ Res. 2024 Jun 21;135(1):174-197. doi: 10.1161/CIRCRESAHA.124.323067. Epub 2024 Jun 20.
3
Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.用新型 Fc 优化抗 CCR8 抗体 BAY 3375968 选择性耗竭肿瘤浸润调节性 T 细胞。
Clin Exp Med. 2024 Jun 10;24(1):122. doi: 10.1007/s10238-024-01362-8.
4
Identification of novel human CC chemokine receptor 8 (CCR8) antagonists via the synthesis of naphthalene amide and sulfonamide isosteres.通过合成萘酰胺和磺酰胺等排体来鉴定新型人 C 型趋化因子受体 8（CCR8）拮抗剂。
Bioorg Chem. 2024 Apr;145:107181. doi: 10.1016/j.bioorg.2024.107181. Epub 2024 Feb 8.
5
Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8.揭示人类趋化因子受体CCR8中非肽配体识别与激活的结构机制。
Sci Adv. 2024 Feb 2;10(5):eadj7500. doi: 10.1126/sciadv.adj7500.
6
Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8.人 CC 趋化因子受体 8 的抗体抑制和趋化因子激活的结构基础。
Nat Commun. 2023 Dec 1;14(1):7940. doi: 10.1038/s41467-023-43601-8.
7
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.S-531011，一种新型抗人 CCR8 抗体，通过耗竭肿瘤浸润的 CCR8 表达调节性 T 细胞诱导强烈的抗肿瘤反应。
Mol Cancer Ther. 2023 Sep 5;22(9):1063-1072. doi: 10.1158/1535-7163.MCT-22-0570.
8
Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer.发现一种用于治疗癌症的强效且选择性的CCR8小分子拮抗剂IPG7236。
J Med Chem. 2023 Apr 13;66(7):4548-4564. doi: 10.1021/acs.jmedchem.3c00030. Epub 2023 Mar 29.
9
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.CCR8 在肿瘤组织与正常组织中的差异表达可使新型 Fc 优化抗 CCR8 抗体 GS-1811 特异性耗尽肿瘤浸润性调节性 T 细胞。
Oncoimmunology. 2022 Nov 4;11(1):2141007. doi: 10.1080/2162402X.2022.2141007. eCollection 2022.
10
Chemokine Receptor-Targeted Therapies: Special Case for CCR8.趋化因子受体靶向疗法：CCR8的特殊情况
Cancers (Basel). 2022 Jan 20;14(3):511. doi: 10.3390/cancers14030511.
Zotero 插件